H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 report. The firm says BioNTech’s $950M acquisition of Biotheus highlights the value potential for Instil Bio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TIL:
- Instil Bio files $200M mixed securities shelf
- Morning Movers: Spotify rises and Groupon sinks following quarterly results
- Instil Bio reports Q3 non-GAAP EPS ($2.55), consensus ($2.11)
- Instil Bio sees cash runway beyond 2026
- Instil Bio initiated with a Market Perform at JMP Securities
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
